Getting Any Better

Quote




And here come the shareholders....

ENDOCHOICE HOLDINGS, INC.
ROBBINS ARROYO LLP: ENDOCHOICE HOLDINGS, INC. (GI) MISLED SHAREHOLDERS ACCORDING TO A RECENTLY FILED CLASS ACTION
Robbins Arroyo LLP announces that a class action complaint was filed against EndoChoice Holdings, Inc. (NYSE: GI) in the Superior Court of the State of Georgia, County of Fulton. The complaint is brought on behalf of all purchasers of EndoChoice securities pursuant to the company’s June 5, 2015 initial public offering (“IPO”) for alleged violations of the Securities Act of 1933 by EndoChoice’s officers and directors. EndoChoice, a medical device company, designs and commercializes various products for gastrointestinal (GI) caregivers in the United States and internationally. Its principal product is known as Fuse, a full spectrum endoscopy system.

ENDOCHOICE ACCUSED OF LYING ABOUT ITS PRINCIPAL PRODUCT
According to the complaint, on June 5, 2015, EndoChoice held its IPO, selling 6,350,000 shares of common stock at $15.00 per share. The Registration Statement the company filed with the U.S. Securities and Exchange Commission emphasized the growth of the GI endoscopy market and EndoChoice’s advantageous position within the market. The Registration Statement went on to tout the capabilities of the Fuse system, stating that the improved clinical and cost outcomes that Fuse enables will lead to its widespread adoption over time. Notably, EndoChoice officials were required to disclose events or uncertainties that have had or are reasonably likely to cause the company’s financial information not to be indicative of future operating results. The complaint alleges that EndoChoice officials issued false statements in the Registration Statement by failing to disclose that the adoption of Fuse had entered into a serious decline.

The truth about the company’s problems did not emerge until November 5, 2015, when EndoChoice announced that its Fuse placements dropped to just 21 in the third quarter compared to 26-27 per quarter in the first half of the year. The next day, J.P. Morgan analysts lowered their price target from $26 to $19 and stated that “a shortfall so soon after the company’s June IPO is certainly concerning and raises questions about the trajectory of Fuse adoption going forward.” On January 8, 2016, the company announced that deals were taking longer than anticipated to close, and J.P. Morgan analysts characterized the company’s Fuse adoption as disappointing. Since its IPO, EndoChoice stock has fallen over 74% to close at $3.87 per share on August 8, 2016.
 












Don't worry. Our fearless leaders told us that it is just a couple of ambulance chasers, nothing more than that. Nothing to see here. Go back to your one demo a month. No excuses.
 



anonymous said:
Probably not as much as MG budgets for his Porsche and fancy lifestyle. A loser in a Porsche is still a loser.
Click to expand...

haha, let's hope that was a short term lease for his sake. also, doesn't the guy filing the complaint realize that there were a lot of reps on vacation when Fuse sales sharply decreased? certainly just a misunderstanding. that and customer's are waiting for get 3. oh, and they had to take some time to weed out the bad reps. probably that the durability of the scopes took a while to improve as well. i'm sure he would drop the complaint if someone just gave him a quick call to explain all of this.

i was there before and during the fuse launch. i remember gc standing up in front of all reps saying the expectation for the first quarter of when fuse gen one launched was 50-55 systems. whoops. and round and round it goes.
 



anonymous said:
A douche on cafe pharma is still a douche
Click to expand...

Well, if I am a douche for pointing out that our fearless leader buys himself a Porsche while he drives the company into the ground (pun intended), then I will gladly accept being called a douche. It still doesn't change the facts, it and shows what kind of a leader he really is...piss poor.
 



anonymous said:
haha, let's hope that was a short term lease for his sake. also, doesn't the guy filing the complaint realize that there were a lot of reps on vacation when Fuse sales sharply decreased? certainly just a misunderstanding. that and customer's are waiting for get 3. oh, and they had to take some time to weed out the bad reps. probably that the durability of the scopes took a while to improve as well. i'm sure he would drop the complaint if someone just gave him a quick call to explain all of this.

i was there before and during the fuse launch. i remember gc standing up in front of all reps saying the expectation for the first quarter of when fuse gen one launched was 50-55 systems. whoops. and round and round it goes.
Click to expand...

I also remember GC saying that within 2 years, we would put Fuji or Pentax out of business and if you sold three systems a year, you were guaranteed to make $300K at EC.

MG also told us that we wouldn't forget our early adopters and any upgrades would be covered free of charge for the entirety of their leases. Now we roll out our Lumos and will charge for the software upgrades.

These two dummies are priceless.
 



anonymous said:
I also remember GC saying that within 2 years, we would put Fuji or Pentax out of business and if you sold three systems a year, you were guaranteed to make $300K at EC.

MG also told us that we wouldn't forget our early adopters and any upgrades would be covered free of charge for the entirety of their leases. Now we roll out our Lumos and will charge for the software upgrades.

These two dummies are priceless.
Click to expand...

They should at least give Lumos to all customers for free for 3 months, then if you don't pay for Lumos, it quits working. If it is really as great as they say, everyone would buy it after 3 months. No dipshit would make a customer purchase it outright at launch when it is just a software upgrade you could sunset on a trial.
 






When Gilreath bought Fuse he had visions of $$$$$$.....well, his vision was partially correct....he has seen $$$$$$, but it is in the form of the company bleeding cash.....what a great case study for a future Duke MBA!
 






Had a recruiter tell me that people make $300k @ EC. I am sure that some do, even if it is not that many. I understand there are 3 lines you are bonused on. What would be the minimum you would have to do on the three lines to make $300k? Territory I am looking @ now is not open. They referred to it as a "bench interview". I understand that it is difficult to switch an account to FUZE. I am not wanting to hear how hard anything is from anyone, I can make a determination about my ability to sell. I just want to know what percentage I would have to grow each of the three lines to make $300k.
Thanks.
 



How could anyone in his/her right mind possibly consider joining this disaster of a company? Have you taken a look at the stock price? You would be better off flipping burgers.....get a clue!
 



anonymous said:
Had a recruiter tell me that people make $300k @ EC. I am sure that some do, even if it is not that many. I understand there are 3 lines you are bonused on. What would be the minimum you would have to do on the three lines to make $300k? Territory I am looking @ now is not open. They referred to it as a "bench interview". I understand that it is difficult to switch an account to FUZE. I am not wanting to hear how hard anything is from anyone, I can make a determination about my ability to sell. I just want to know what percentage I would have to grow each of the three lines to make $300k.
Thanks.
Click to expand...

You should start be learning how to spell Fuse. You aren't selling Fuze Tea
 









Another example where someone is able to insult what a person has posted, but they are not able to challenge what the person is saying.

People are abandoning this sinking ship at an increasing rate; fuse continues to generate disappointing sales; the stock is in the toilet.

I get it, with Endochoice insulting someone is much easier than challenging their realistic assessment of a company that is floundering, and has been for quite some time.
 



anonymous said:
Another example where someone is able to insult what a person has posted, but they are not able to challenge what the person is saying.

People are abandoning this sinking ship at an increasing rate; fuse continues to generate disappointing sales; the stock is in the toilet.

I get it, with Endochoice insulting someone is much easier than challenging their realistic assessment of a company that is floundering, and has been for quite some time.
Click to expand...

Do you work here? If so, you have the right to say what you want about the company. Like it or not, there are actually people here that believe in what we are doing with Fuse. We are trying to change GI and there is no argument about how great the technology is.

If you don't work here, why continue to bash the company? What satisfaction does it give you?
 



Top Bottom
Back
Quote